Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease
Purpose of Review
The increased use of biologic agents over the past two decades has led to a reappraisal of the role of the immunomodulators (thiopurines and methotrexate) in the treatment of inflammatory bowel disease. The purpose of this review is to summarize recent data on the use of thiopurines and methotrexate either as monotherapy or as part of combination therapy with biologic agents.
Recent studies have addressed the need for concomitant immunomodulatory therapy in treatment-naïve patients starting anti-TNF-α therapy, the appropriate dose of the immunomodulator in this setting, the minimum duration of combination therapy, and the possible mechanisms by which immunomodulators enhance the effectiveness of anti-TNF-α agents. Little is known about the role of immunomodulators in combination with agents belonging to other classes of biologic therapies. Recent studies have shown that methotrexate is not effective in inducing or maintaining remission in ulcerative colitis. Finally, several studies have broadened our understanding of the infection and malignancy risks of the immunomodulators.
Immunomodulators continue to have a place in the treatment of inflammatory bowel disease. However, with the ever-increasing list of biologic agents, properly positioning the immunomodulators within the overall therapeutic scheme is a complicated task. In order to optimize outcomes, each patient requires an individualized approach, which takes into account risks, benefits, cost, alternatives, and patient preferences.
KeywordsImmunomodulator Thiopurines Methotrexate Crohn’s disease Ulcerative colitis Inflammatory bowel disease
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Feagan BG, Rochon J, Fedorak RN, et al; for the North American Crohn’s Study Group Investigators. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995;332(5):292–7.Google Scholar
- 5.Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383–95.Google Scholar
- 7.Matsumoto T, Motoya S, Watanabe K, et al; DIAMOND study group. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J Crohns Colitis 2016;10(11):1259–66.Google Scholar
- 12.Colombel JF, Adedokun OJ, Gasink C, et al. Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn’s disease: a SONIC post-hoc analysis [AGA abstract 134]. Gastroenterology. 2017;152(5)(suppl 1): S37–8.Google Scholar
- 13.• Bouguen G, Sninsky C, Tang KL, et al. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015;21(3):606-14. Data supporting the concept that AZA increases IFX concentrations but also has an independent anti-inflammatory effect in patients with CD. Google Scholar
- 18.Kierkuś J, Iwańczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Łazowska I, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(5):580–5.CrossRefGoogle Scholar
- 19.Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699–710.Google Scholar
- 20.Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369(8):711–21.Google Scholar
- 21.Colombel JF, Loftus EV, Siegel CA, et al. Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1 [AGA abstract Sa1271]. Gastroenterology. 2015;148(4)(suppl 1);S277–8.Google Scholar
- 22.Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for inflammatory bowel disease (SWIBREG). Scand J Gastroenterol. 2017;52(6–7):722–9.CrossRefGoogle Scholar
- 23.Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–601. e2CrossRefGoogle Scholar
- 28.Feagan BG, Sandborn WJ, Gasink C, et al; UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375(20):1946–60.Google Scholar
- 30.Beaugerie L, Brousse N, Bouvier AM, et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617–25.Google Scholar
- 31.•• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–86. Study of the French National Health Insurance claim database that found that both anti-TNFα agents and thiopurines were associated with an increased risk of lymphoma. CrossRefPubMedCentralGoogle Scholar
- 32.Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13(13):2233–40.e1–2;quiz e177–8.Google Scholar
- 34.Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111(12):1806–15.CrossRefGoogle Scholar
- 52.Thompson G, Pepperell D, Lawrence I, McGettigan BD. Crohn’s disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab. BMJ Case Rep. 2017;2017:pii:bcr2016218578. doi: https://doi.org/10.1136/bcr-2016-218578.
- 58.•• Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901–14.e3. Large pediatric study estimated the risk of HLH among thiopurine patients at 0.29 per 10,000 patient-years (95% CI, 0.09–0.68). Google Scholar
- 63.•• Carbonnel F, Colombel JF, Filippi J, et al; European Crohn’s and Colitis Organisation and the Groupe d’Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150(2):380–8.e4. Randomized, placebo-controlled trial showing that methotrexate was not effective in inducing remission in UC. Google Scholar
- 64.•• Herfarth HH, Barnes EL, Jackson S, et al; MERIT-UC study group. Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study [ECCO abstract P390]. J Crohns Colitis. 2018;12(suppl 1):S300–1. Randomized, placebo-controlled trial showing that methotrexate was not effective in maintaining remission in UC. Google Scholar